Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: A national multicentre cross-sectional study

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 9, 2013, Pages 952-960

  Laroche, Marie Laure ^a,b   Perault Pochat, Marie Christine ^c   Ingrand, Isabelle ^c   Merle, Louis ^a,b   Kreft Jais, Carmen ^d,e   Castot Villepelet, Anne ^d,f   Durrieu, Geneviève ^g,h   Gras, Valérie ⁱ   Guy, Claire ^j   Jean Pastor, Marie Josèphe ^k   Jonville Béra, Annie Pierre ^l   Merlet Chicoine, Isabelle ^c   Miremont Salamé, Ghada ^m,n   Nourhashemi, Fati ^g   Charmes, Jean Pierre ^o  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LIMOGES   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d AFSSAPS   (France)

^e Institut National de Prevention et d'Education Pour la Sante   (France)

^f Agence Régionale de la Santé ARS Ile de France   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^k Regional Centre of Pharmacovigilance   (France)

^l UNIVERSITY HOSPITAL OF TOURS   (France)

^m University Hospital   (France)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o Centre of Dialysis   (France)

more..

Author keywords

Adverse drug reaction; Alzheimer's disease; Cross sectional study; Dementia; Pharmacoepidemiology; Pharmacovigilance

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMOXICILLIN PLUS CLAVULANIC ACID; ATENOLOL; BENAZEPRIL; BISOPROLOL; BROMAZEPAM; CIPROFLOXACIN; CLONAZEPAM; CLOPIDOGREL; CORTICOSTEROID; DONEPEZIL; DOXAZOSIN; ENALAPRIL; ESCITALOPRAM; FUROSEMIDE; GALANTAMINE; HALOPERIDOL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INSULIN; LORAZEPAM; METFORMIN; NICORANDIL; OXAZEPAM; RISPERIDONE; RIVASTIGMINE; UNINDEXED DRUG; VENLAFAXINE; ZOPICLONE;

ADULT; ADVERSE DRUG REACTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CROSS-SECTIONAL STUDY; DEMENTIA; DIARRHEA; DROWSINESS; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; HEMATOMA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REHABILITATION CARE; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION; ALZHEIMER'S DISEASE; CROSS-SECTIONAL STUDY; DEMENTIA; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CROSS-SECTIONAL STUDIES; DEMENTIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FRANCE; HUMANS; MIDDLE AGED; PHARMACOVIGILANCE; PREVALENCE; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 84882691447     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3471     Document Type: Article

References (33)

1. Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287: 2335-8.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Author; Washington, DC: 2000.
3. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
4. Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prévalence de la démence et de la maladie d'Alzheimer chez les personnes de 75 ans et plus: données réactualisées de la cohorte Paquid. Rev Neurol 2003; 159:405-11.
5. Gallez C. Rapport sur la maladie d'Alzheimer et les maladies apparentées. Office Parlementaire d'Evaluation des Politiques de Santé, 2005, 256 p. http://www.assemblee-nationale.fr/12/rap-off/i2454.asp
6. Ruscin JM, Semla TP. Assessment of medication management skills in older outpatients. Ann Pharmacother 1996; 30: 1083-8.
7. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988; 472: 371-89.
8. Merle L, Laroche ML, Dantoine T, et al. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22: 375-92.
9. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001; 18: 853-62.
10. Schück S, Bentué-Ferrer D, Beaufils C, et al. Adverse effects and drugs for Alzheimer's disease. Therapie 1999; 54: 237-42.
11. Pariente A, Sanctussy DJ, Miremont-Salamé G, et al. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs 2010; 24: 55-63.
12. Moore A, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15: 15-28.
13. Chavant F, Favrelière S, Lafay-Chebassier C, et al. Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 2011; 72: 898-904.
14. Onder G, Gambassi G, Scales CJ, et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol 2002; 58: 371-7.
15. Ganjavi H, Herrmann N, Rochon PA, et al. Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord 2007; 23: 395-400.
16. Nourhashémi F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Assoc Disord Dis 2001; 15:21-5.
17. Granjon C, Beyens MN, Frederico D, et al. Existe-t-il un sur-risque d'accidents médicamenteux chez les sujets âgés atteints de troubles cognitifs ? A propos de 82 déments hospitalisés. Neurol Psy Gériatr 2006; 6: 21-8 [In French].
18. Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogenic medication: estimation of its prevalence in French public hospitals. Therapie 1999; 54: 21-7.
19. Laroche ML, Charmes JP, Nouaille Y, et al. Impact of hospitalization in an acute medical geriatric unit on potentially inappropriate medication use. Drugs Aging 2006; 23: 49-59.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
21. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-8.
22. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985;2(8463): 1056-8.
23. WHO Technical Report. Geneva: World Health Organization 1972:498.
24. Olivier P, Caron J, Haramburu F, et al. Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale. Therapie 2005; 60: 39-45.
25. Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. Journal J Gerontol A Biol Sci Med 1998; 53: M59-63.
26. McCormick WC, Kukull WA, van Belle G, et al. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. J Am Geriatr Soc 1994; 42: 517-521.
27. McCormick WC, Kukull WA, van Belle G, et al. The effect of diagnosing Alzheimer's disease on frequency of physician visits: a case-control study. J Gen Intern Med 1995; 10: 187-93.
28. Atri A. Effective pharmacological management of Alzheimer's disease. Am J Manag Care 2011; 17: S346-55.
29. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5: 245-55.
30. Haute Autorité de Santé. Maladie d'Alzheimer et maladies apparentées : prise en charge des troubles du comportement perturbateurs. Recommandations 2009. http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-07/maladie_dalzheimer-troubles_du_comportement_perturbateurs-recommandations.pdf (Available 5/5/2013)
31. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 2010; 24: 729-39.
32. Ballard C, Corbett A, Chitramohan R, et al. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry 2009; 22:532-40.
33. Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. Journal J Gerontol A Biol Sci Med 2002; 57: M173-7.